Today's Top Story

EPO decision strengthens UC’s CRISPR patent position in Europe as Editas looks to Cas9 alternatives

A decision at the European Patent Office has confirmed that the CRISPR IP landscape is going to look much different in Europe than it does in the U.S., contributing to the growing complexity of global ...

Company News

Jan. 17 Company Quick Takes: FDA expands label of Novo’s Ozempic; plus Intercept, Durect, Coherus-Innovent, CoImmune-Formula and Momenta

Label expansion for Novo’s Ozempic FDA approved Ozempic subcutaneous semaglutide from Novo Nordisk A/S (CSE:NOVO B; NYSE:NOVO) to reduce the risk of major adverse cardiovascular events in adults with ...

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

Jiangsu Hengrui Medicine Co Ltd. (Shanghai:600276) said Piaoyang Sun will step down as chairman. Sun, who has led the company for 30 years, will continue to serve on the board’s strategy committee and ...

Financial News

Sofinnova Partners vet Tordjman launches Jeito with €200M first biotech fund

Paris-based Jeito Capital launched Monday with the €200 million ($223.1 million) close of its first fund, which the firm will invest in 15 therapeutics start-ups, primarily in Europe. Jeito founder ...

I-Mab dips in NASDAQ debut, first in years for an innovative Chinese biopharma

Shares of I-Mab slipped 11% in their first day of trading Friday after the Shanghai-based company priced its IPO on NASDAQ within its proposed range, raising $104 million to fund its cross-border ...

BioCentury & Getty ImagesNovo seeks to REPAIR funding in antibiotics companies

In response to an expanding funding gap for antimicrobial resistance companies, Novo Holdings is expanding the remit of its early stage REPAIR Impact Fund to include investments as late as Phase II ...

Define Ventures closes first digital health fund with $87M

Led by a former Kleiner Perkins partner, Define Ventures launched Monday with an $87 million first fund, which will invest in early stage digital health companies. Founder and Managing Partner Lynne ...

BioCentury Extra ISSN 2642-3812